Clinical outcomes in correlation with pharmacokinetics and CYP2D6 genotypes in metastatic breast cancer patients on tamoxifen

American Journal of Hematology/ Oncology

Volumn 7, Issue 2, 2008, Pages 65-67

  Ro, Jungsil ^a   Lim, Hyeong Seok ^b   Han, Hye Suk ^a  

^a National Cancer Center   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DOXORUBICIN; PACLITAXEL; TAMOXIFEN;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CASE REPORT; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT;

EID: 40549109256     PISSN: 15429520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N Eng J Med. 1998;339:1609-1618.
2. Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N- desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989;49:2175-2183.
3. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85:151-159.
4. Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002;30:869-874.
5. Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310:1062-1075.
6. Coller JK, Krebsfaenger N, Klein K, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antiestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol. 2002;54:157-167.
7. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flushes. J Clin Oncol. 2005;23:9312-9318.
8. Gjerde J, Hauglid M, Breilid H, et al. Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Res Treat. 2005;94:S236.
9. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30-39.
10. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;23:1758-1764.
11. Lim HS, Lee HJ, Lee KS, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007;25:3837-3845.
12. Tamoxifen for early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
13. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113-121.
14. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;20:5187-5193.
15. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271.
16. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med. 2004;350:1081-1092.
17. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455-462.